

DAFTAR PUSTAKA

1. Setiati S, Alwi I, Sudoyo AW, Simadibrata M, Setyohadi B, Syam AF. Immunopatogenesis lupus eritematosus sistemik. In: Buku ajar ilmu penyakit dalam. 6th ed. Jakarta: Interna Publishing; 2014. p. 3331-45.
2. Barber MRW, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow NY, et al. Global epidemiology of systemic lupus erythematosus. *Nat Rev Rheumatol*. 2021;17(9):515-32.
3. Izmirly PM, Parton H, Wang L, McCune WJ, Lim SS, Drenkard C, et al. Prevalence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the Centers for Disease Control and Prevention National Lupus Registries. *Arthritis Rheumatol*. 2021;73(6):991-6.
4. Tanaka Y, O'Neill S, Li M, Tsai IC, Yang YW. Systemic lupus erythematosus: targeted literature review of the epidemiology, current treatment, and disease burden in the Asia Pacific region. *Arthritis Care Res*. 2022;74(2):187-98.
5. Leong PY, Huang JY, Chiou JY, Bai YC, Wei JCC. The prevalence and incidence of systemic lupus erythematosus in Taiwan: a nationwide population-based study. *Sci Rep*. 2021;11(1):5631.
6. Dein E, Ingolia A, Connolly C, Manno R, Timlin H. Anakinra for recurrent fevers in systemic lupus erythematosus. *Cureus*. 2018;10(1):e2010.
7. Perhimpunan Reumatologi Indonesia. Diagnosis dan pengelolaan lupus eritematosus sistemik. Jakarta: Perhimpunan Reumatologi Indonesia; 2019.
8. Hamijoyo L, Candrianita S, Rahmadi AR, Dewi S, Darmawan G, Suryajaya BS, et al. The clinical characteristics of systemic lupus erythematosus patients in Indonesia: a cohort registry from an Indonesia-based tertiary referral hospital. *Lupus*. 2019;28(13):1604-9.
9. Dorner T, Furie R. Novel paradigms in systemic lupus erythematosus. *Lancet*. 2019;393(10188):2344-58.
10. Zen M, Salmaso L, Barbiellini Amidei C, Fedeli U, Bellio S, Iaccarino L, et al. Mortality and causes of death in systemic lupus erythematosus over the last decade: data from a large population-based study. *Eur J Intern Med*. 2023;112:45-51.

11. Catalina MD, Owen KA, Labonte AC, Grammer AC, Lipsky PE. The pathogenesis of systemic lupus erythematosus: harnessing big data to understand the molecular basis of lupus. *J Autoimmun.* 2020;110:102359.
12. Moulton VR, Suarez-Fueyo A, Meidan E, Li H, Mizui M, Tsokos GC. Pathogenesis of human systemic lupus erythematosus: a cellular perspective. *Trends Mol Med.* 2017;23(7):615-35.
13. Hahn BH. Systemic lupus erythematosus. In: Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, editors. *Harrison's principles of internal medicine.* 20th ed. New York: McGraw Hill; 2018. p. 2515-26.
14. Engel P, Gómez-Puerta JA, Ramos-Casals M, Lozano F, Bosch X. Therapeutic targeting of B cells for rheumatic autoimmune diseases. *Pharmacol Rev.* 2011;63(1):127-56.
15. Fujimoto M, Hamaguchi Y, Yazawa N, Komura K, Matsushita T, Kaji K, et al. B cell antigen receptor signaling in patients with systemic sclerosis. *J Dermatol Sci.* 2013;72(2):177-9.
16. Mok CC, Hamijoyo L, Kasitanon N. The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus. *Lancet Rheumatol.* 2021;3(7):e517–e531. doi:10.1016/S2665-9913(21)00009-6.
17. Kasjmir YI, Handono K, Wijaya LK, Hamijoyo L, Albar Z, Kalim H, et al. Diagnosis dan pengelolaan lupus eritematosus sistemik. In: Setiati S, Alwi I, Sudoyo AW, Simadibrata M, Setyohadi B, Syam AF, editors. *Buku ajar ilmu penyakit dalam.* Vol III. 6th ed. Jakarta: Interna Publishing; 2014. p. 3360-77.
18. Galarza-Maldonado C, Kourilovitch MR, Molineros JE, Cardiel MH, Zurita L, Soroka NF, et al. The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus. *Autoimmun Rev.* 2010;10(2):108-11.
19. Ibañez D, Gladman DD, Touma Z, Nikpour M, Urowitz MB. Optimal frequency of visits for patients with systemic lupus erythematosus to measure disease activity over time. *J Rheumatol.* 2011;38(1):60-3.

20. Vogenberg FR. Predictive and prognostic models: implications for healthcare decision-making in modern recession. *Am Health Drug Benefits*. 2009;2(6):218-22.
21. Ponticelli C, Moroni G. New therapies for lupus nephritis. *Clin J Am Soc Nephrol*. 2006;1(5):863-8.
22. Ingvarsson RF, Landgren AJ, Bengtsson AA, Jonsen A. Good survival rates in systemic lupus erythematosus in southern Sweden, while the mortality rate remains increased compared with the population. *Lupus*. 2019;28(12):1488-94.
23. Doria A, Iaccarino L, Ghirardello A, Zampieri S, Arienti S, Sarzi-Puttini P, et al. Long-term prognosis and causes of death in systemic lupus erythematosus. *Am J Med*. 2006;119(8):700-6.
24. Ocampo-Piraquive V, Nieto-Aristizábal I, Cañas CA, Tobón GJ. Mortality in systemic lupus erythematosus: causes, predictors and interventions. *Expert Rev Clin Immunol*. 2018;14(12):1043-53.
25. Tjan B, Kambayana G, Kurniari PK. Gambaran profil systemic lupus erythematosus (SLE) dan lupus nefritis di Rumah Sakit Umum Pusat Sanglah. *Jurnal Penyakit Dalam Udayana*. 2022;6(2):31-5.
26. Odunlami GJ, Ajibade A, Omotoso BA, Hassan MO, Adefidipe AA, Olanrewaju FO, et al. Clinical and laboratory profiles of systemic lupus erythematosus patients in a new rheumatology clinic in southwestern Nigeria. *Reumatologia*. 2024;62(2):83-93.
27. Gergianaki I, Garantziotis P, Adamichou C, Saridakis I, Spyrou G, Sidiropoulos P, et al. High comorbidity burden in patients with SLE: data from the community-based Lupus Registry of Crete. *J Clin Med*. 2021;10(5):998.
28. Tselios K, Gladman DD, Urowitz MB. Metrics in disease activity measures in systemic lupus erythematosus. In: Touma Z, editor. *Outcome measures and metrics in systemic lupus erythematosus*. Cham: Springer; 2021. p. 111-46.
29. Uribe AG, Vila LM, McGwin G Jr, Sanchez ML, Reveille JD, Alarcon GS. The Systemic Lupus Activity Measure-Revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a Modified SLEDAI-

- 2K are adequate instruments to measure disease activity in systemic lupus erythematosus. *J Rheumatol*. 2004;31(10):1934-40.
30. Zonana-Nacach A, Yañez P, Jiménez-Balderas FJ, Camargo-Coronel A. Disease activity, damage and survival in Mexican patients with acute severe systemic lupus erythematosus. *Lupus*. 2007;16(12):997-1000.
 31. Rahman P, Gladman DD, Urowitz MB, Hallett D, Tam LS. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. *Lupus*. 2001;10(2):93-6.
 32. Kriswiastiny R, Mustofa FL, Pramesti W, Azhari AH. Hubungan aktivitas penyakit systemic lupus erythematosus (SLE) berdasarkan skor MEX SLEDAI dengan kualitas hidup. *Maheesa: Malahayati Health Student Journal*. 2022;2(3):419-27.
 33. Silvagni E, Elefante E, Signorini V, Tani C, Mosca M. Systemic lupus erythematosus: one year in review 2023. *Clin Exp Rheumatol*. 2023;41(5):997-1008.
 34. Yu H, Nagafuchi Y, Fujio K. Clinical and immunological biomarkers for systemic lupus erythematosus. *Biomolecules*. 2021;11(7):928.
 35. Mughales JA. Anti-nuclear antibodies patterns in patients with systemic lupus erythematosus and their correlation with other diagnostic immunological parameters. *Front Immunol*. 2022;13:850759.
 36. Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. *Ann Rheum Dis*. 2014;73(1):17-23.
 37. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. *Arthritis Rheumatol*. 2019;71(9):1400-12.
 38. Dahlan MS. Penelitian prognostik dan sistem skoring: disertai praktik dengan SPSS dan STATA. Jakarta: Alqaprint; 2011.

39. Alian S, Khalil S, Zaghlol RS. Charlson comorbidity index in patients with systemic lupus erythematosus in Egypt and its relation with disease characteristics. *Indian J Rheumatol*. 2019;14(4):277-82.
40. Fava A, Petri M. Systemic lupus erythematosus: diagnosis and clinical management. *J Autoimmun*. 2019;96:1-13.
41. Lorenzo-Vizcaya A, Isenberg D. Analysis of trends and causes of death in SLE patients over a 40-years period in a cohort of patients in the United Kingdom. *Lupus*. 2021;30(5):702-6.
42. Bernatsky S, Clarke A, Ramsey-Goldman R, Joseph L, Boivin JF, Rajan R, et al. Malignancy and systemic lupus erythematosus. *Curr Rheumatol Rep*. 2002;4(4):351-8.
43. Abu-Shakra M, Ehrenfeld M, Shoenfeld Y. Systemic lupus erythematosus and cancer: associated or not? *Lupus*. 2002;11(3):137-44.
44. Doria A, Shoenfeld Y, Wu R, Gambari PF, Puato M, Ghirardello A, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. *Ann Rheum Dis*. 2003;62(11):1071-7.
45. Doria A, Shoenfeld Y, Pauletto P. Premature coronary disease in systemic lupus. *N Engl J Med*. 2004;350(15):1571-5.
46. Doria A, Sherer Y, Meroni PL, Shoenfeld Y. Inflammation and accelerated atherosclerosis: basic mechanisms. *Rheum Dis Clin North Am*. 2005;31(2):355-62.
47. Stojan G, Petri M. Atherosclerosis in systemic lupus erythematosus. *J Cardiovasc Pharmacol*. 2013;62(3):255-62.
48. Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. *Am J Epidemiol*. 2012;176(8):708-19.
49. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. *Ann Intern Med*. 2004;141(10):764-70.
50. Sazliyana S, Mohd Shahrir MS, Kong NCT, Tan HJ, Hamidon BB, Azmi MT. Disease activity and damage in hospitalized lupus patients: a Sabah perspective. *Med J Malaysia*. 2020;75(1):24-9.

51. Zhang S, Xu M, Zhang W, Li H, Wang J, Zhu L, et al. Predictors of improvement in disease activity in first hospitalized patients with systemic lupus erythematosus: a multicenter retrospective study of a Chinese cohort. *Clin Rheumatol*. 2022;41(10):3093-102.
52. Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, Wallace DJ, et al. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. *Ann Rheum Dis*. 2011;70(10):1726-32.
53. Man BL, Mok CC. Serositis related to systemic lupus erythematosus: prevalence and outcome. *Lupus*. 2005;14(10):822-6.
54. Yap DY, Lai KN. Pathogenesis of renal disease in systemic lupus erythematosus--the role of autoantibodies and lymphocytes subset abnormalities. *Int J Mol Sci*. 2015;16(4):7917-31.
55. Bengtsson C, Andersson SE, Edvinsson L, Edvinsson ML, Sturfelt G, Nived O, et al. Cardiovascular disease in systemic lupus erythematosus: a Swedish nationwide study of incident cases. *Rheumatology (Oxford)*. 2015;60(1):256-64.
56. Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. *Semin Arthritis Rheum*. 2013;43(1):77-95.
57. Giannelou M, Mavragani CP. Cardiovascular disease in systemic lupus erythematosus: a comprehensive update. *J Autoimmun*. 2020;113:102481.
58. Gustafsson JT, Herlitz Lindberg M, Gunnarsson I, Pettersson S, Elvin K, Öhrvik J, et al. Excess atherosclerosis in systemic lupus erythematosus a matter of renal involvement: case control study of 281 SLE patients and 281 individually matched population controls. *PLoS One*. 2017;12(4):e0174572.
59. Nikpour M, Urowitz MB, Ibanez D, Harvey PJ, Gladman DD. Contribution of traditional risk factors to coronary artery disease risk in patients with systemic lupus erythematosus. *J Rheumatol*. 2009;36(11):2454-61.
60. Prasetyo M, Priantono D, Sukmana N, Nelwan EJ. Mortality incidence of systemic lupus erythematosus in Dr. Soetomo General Hospital Surabaya. *Indonesian J Rheumatol*. 2022;14(2):89-94.

61. Sharma A, Shamanna SB, Kumar S, Wanchu A, Bambery P, Singh S, et al. Pattern of hematological manifestations in patients with systemic lupus erythematosus at presentation: a tertiary care center experience. *Indian J Rheumatol*. 2018;13(2):102-9.
62. Gormezano NW, Kern D, Pereira OL, Esteves GC, Sallum AM, Aikawa NE, et al. Autoimmune hemolytic anemia in systemic lupus erythematosus at diagnosis: differences between pediatric and adult patients. *Lupus*. 2017;26(4):426-30.
63. Domingues V, Levinson BA, Bornkamp N, Goldberg JD, Buyon J, Belmont HM, et al. Prevalence of the American College of Rheumatology hematological classification criteria and associations with serological and clinical variables in 460 systemic lupus erythematosus patients. *Lupus*. 2015;24(4-5):382-91.
64. Newman K, Owlia MB, El-Hemaidi I, Akhtari M. Management of immune cytopenias in patients with systemic lupus erythematosus - old and new. *Autoimmun Rev*. 2013;12(7):784-91.
65. Morales E, Galindo M, Trujillo H, Praga M. Update on lupus nephritis: looking for a new vision. *Nephron*. 2021;145(1):1-13.
66. Birmingham DJ, Rovin BH, Shidham G, Bissell M, Nagaraja HN, Hebert LA, et al. Relationship between albuminuria and total proteinuria in systemic lupus erythematosus nephritis: diagnostic and therapeutic implications. *Clin J Am Soc Nephrol*. 2008;3(4):1028-33.
67. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. *N Engl J Med*. 2003;349(16):1526-33.
68. Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. *Ann Rheum Dis*. 2017;76(3):476-85.

69. Hoffman IE, Peene I, Meheus L, Huizinga TW, Cebecauer L, Isenberg D, et al. Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. *Ann Rheum Dis*. 2004;63(9):1155-8.
70. Didier K, Bolko L, Giusti D, Toquet S, Robbins A, Antonicelli F, et al. Autoantibodies associated with connective tissue diseases: what meaning for clinicians? *Front Immunol*. 2018;9:541.
71. Jonsson H, Nived O, Sturfelt G, Silman A. Estimating the incidence of systemic lupus erythematosus in a defined population using multiple sources of retrieval. *Br J Rheumatol*. 1990;29(3):185-8.
72. Singh JA, Cleveland JD. Hospitalization and mortality among patients with systemic lupus erythematosus in the United States: update from a national database. *Arthritis Rheumatol*. 2021;73(5):769-80.
73. Velo-García A, Castro SG, Isenberg DA. The diagnosis and management of the haematologic manifestations of lupus. *J Autoimmun*. 2016;74:139-60.
74. Gatto M, Zen M, Iaccarino L, Doria A. New therapeutic strategies in systemic lupus erythematosus management. *Nat Rev Rheumatol*. 2019;15(1):30-48.
75. Ripley BJ, Goncalves B, Isenberg DA, Latchman DS, Rahman A. Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia. *Ann Rheum Dis*. 2005;64(6):849-53.
76. Kokori SI, Ioannidis JP, Voulgarelis M, Tzioufas AG, Moutsopoulos HM. Autoimmune hemolytic anemia in patients with systemic lupus erythematosus. *Am J Med*. 2000;108(3):198-204.
77. Voulgarelis M, Kokori SI, Ioannidis JP, Tzioufas AG, Kyriaki D, Moutsopoulos HM. Anaemia in systemic lupus erythematosus: aetiological profile and the role of erythropoietin. *Ann Rheum Dis*. 2000;59(3):217-22.
78. Sabio JM, Vargas-Hitos JA, Martinez-Bordonado J, Navarrete-Navarrete N, Díaz-Chamorro A, Olvera-Porcel C, et al. Association between low hemoglobin levels and cardiovascular events in patients with systemic lupus erythematosus. *Lupus*. 2018;30(8):1250-9.
79. Wielosz E, Dryglewska M, Majdan M. Serological profile of patients with systemic lupus erythematosus positive for anti-topoisomerase I antibodies. *Rheumatol Int*. 2018;34(8):1065-71.

80. Pakozdi A, Nihtyanova S, Moinszadeh P, Ong VH, Black CM, Denton CP. Clinical and serological hallmarks of systemic sclerosis overlap syndromes. *J Rheumatol*. 2011;38(11):2406-14.
81. Jacobsen S, Halberg P, Ullman S, Van Venrooij WJ, Høier-Madsen M, Wiik A, et al. Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis. *Br J Rheumatol*. 1998;37(1):39-45.
82. Hénault J, Tremblay M, Clément J, Raymond Y, Senécal JL. Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis. *Arthritis Rheum*. 2004;50(10):3265-74.
83. Foocharoen C, Netwijitpan S, Mahakkanukrauh A, Suwannaroj S, Nanagara R. Clinical characteristics of systemic sclerosis overlap syndromes: comparisons with pure scleroderma. *Int J Rheum Dis*. 2012;15(6):e110-5.
84. Hanly JG, Li Q, Su L, Urowitz MB, Gordon C, Bae SC, et al. Cerebrovascular events in systemic lupus erythematosus: results from an international inception cohort study. *Arthritis Care Res*. 2018;70(10):1478-87.
85. Yoshio T, Okamoto H, Kurasawa K, Dei Y, Hirohata S, Minota S. IL-6, IL-8, IP-10, MCP-1 and G-CSF are significantly increased in cerebrospinal fluid but not in sera of patients with central neuropsychiatric lupus erythematosus. *Lupus*. 2016;25(10):997-1003.
86. Mikdashi J, Handwerker B. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. *Rheumatology*. 2004;43(12):1555-60.
87. Pons-Estel GJ, Catoggio LJ, Cardiel MH, Bonfa E, Caeiro F, Sato E, et al. Lupus in Latin-American patients: lessons from the GLADEL cohort. *Lupus*. 2015;24(6):536-45.
88. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. *Ann Rheum Dis*. 2010;69(1):61-4.
89. Bao L, Cunningham PN, Quigg RJ. Complement in lupus nephritis: new perspectives. *Kidney Dis (Basel)*. 2015;1(2):91-9.

90. Reich HN, Gladman DD, Urowitz MB, Bargman JM, Hladunewich MA, Lou W, et al. Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus. *Kidney Int.* 2011;79(8):914-20.
91. Chang SH, Park JK, Lee YJ, Yang JA, Lee EY, Song YW, et al. Charlson comorbidity index is an important prognostic factor for long-term survival outcomes in Korean patients with systemic lupus erythematosus. *Lupus.* 2014;23(14):1480-7.
92. Yap DY, Tang CS, Ma MK, Lam MF, Chan TM. Survival analysis and causes of mortality in patients with lupus nephritis. *Nephrol Dial Transplant.* 2012;27(8):3248-54.
93. Cortes S, Chambers S, Jerónimo A, Isenberg D. Diabetes mellitus complicating systemic lupus erythematosus - analysis of the UCL lupus cohort and review of the literature. *Lupus.* 2008;17(11):977-80.
94. Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, Boivin JF, Petri M, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. *J Autoimmun.* 2013;42:130-5.
95. Feng X, Pan W, Liu L, Wu M, Ding F, Hu H, et al. Prognosis for hospitalized patients with systemic lupus erythematosus in China: 5-year update of the Jiangsu cohort. *PLoS One.* 2016;11(12):e0168619.
96. Bengtsson AA, Pettersson Å, Wichert S, Gullstrand B, Hansson M, Hellmark T, et al. Low production of reactive oxygen species in granulocytes is associated with organ damage in systemic lupus erythematosus. *Arthritis Res Ther.* 2014;16(3):R120.
97. Feldman CH, Hiraki LT, Winkelmayer WC, Marty FM, Franklin JM, Kim SC, et al. Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. *Arthritis Rheumatol.* 2015;67(6):1577-85.
98. Hersh AO, Trupin L, Yazdany J, Panopalis P, Julian L, Katz P, et al. Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythematosus. *Arthritis Care Res.* 2010;62(8):1152-9.

99. Tucker LB, Uribe AG, Fernández M, Vilá LM, McGwin G, Apte M, et al. Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). *Lupus*. 2008;17(4):314-22.
100. Medlin JL, Hansen KE, Fitz SR, Bartels CM. A systematic review and meta-analysis of cutaneous manifestations in late- versus early-onset systemic lupus erythematosus. *Semin Arthritis Rheum*. 2016;45(6):691-7.
101. Bruce IN, O'Keeffe AG, Farewell V, Hanly JG, Manzi S, Su L, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. *Ann Rheum Dis*. 2015;74(9):1706-13.
102. Petri M, Purvey S, Fang H, Magder LS. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. *Arthritis Rheum*. 2012;64(12):4021-8.
103. Parodis I, Stockfelt M, Sjöwall C. B cell therapy in systemic lupus erythematosus: from rationale to clinical practice. *Front Med*. 2020;7:316.
104. Pons-Estel BA, Catoggio LJ, Cardiel MH, Soriano ER, Gentiletti S, Villa AR, et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among "Hispanics". *Medicine*. 2004;83(1):1-17.
105. Alarcón GS, McGwin G Jr, Petri M, Reveille JD, Ramsey-Goldman R, Kimberly RP, et al. Time to renal disease and end-stage renal disease in PROFILE: a multiethnic lupus cohort. *PLoS Med*. 2006;3(10):e396.
106. Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus erythematosus. *Medicine*. 2006;85(3):147-56.
107. Tamirou F, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Fiehn C, et al. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. *Ann Rheum Dis*. 2016;75(3):526-31.
108. Jung JH, Soh MS, Ahn YH, Um YJ, Jung JY, Suh CH, et al. Thrombocytopenia in systemic lupus erythematosus: clinical manifestations, treatment, and prognosis in 230 patients. *Medicine*. 2016;95(6):e2818.

109. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. *Medicine*. 2003;82(5):299-308.
110. Jiang MY, Hwang JC, Feng IJ. Impact of diabetes mellitus on the risk of end-stage renal disease in patients with systemic lupus erythematosus. *Sci Rep*. 2018;8(1):6008.
111. Pisetsky DS, Thompson DK, Wajdula J, Diehl A, Sridharan S. Variability in antinuclear antibody testing to assess patient eligibility for clinical trials of novel treatments for systemic lupus erythematosus. *Arthritis Rheumatol*. 2019;71(9):1534-8.
112. Choi MY, Clarke AE, St Pierre Y, Hanly JG, Urowitz MB, Romero-Diaz J, et al. Antinuclear antibody-negative systemic lupus erythematosus in an international inception cohort. *Arthritis Care Res*. 2019;71(7):893-902.
113. Vilá LM, Alarcón GS, McGwin G Jr, Bastian HM, Reveille JD, Scofield RH, et al. Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations. *Rheumatology*. 2004;43(3):358-63.
114. Memet B, Ginzler E. Pulmonary manifestations of systemic lupus erythematosus. *Semin Respir Crit Care Med*. 2007;28(4):441-50.
115. Kao AH, Lertratanakul A, Elliott JR, Sattar A, Santelices L, Shaw P, et al. Relation of carotid intima-media thickness and plaque with incident cardiovascular events in women with systemic lupus erythematosus. *Am J Cardiol*. 2013;112(7):1025-32.
116. Peschken CA, Katz SJ, Silverman E, Pope JE, Fortin PR, Pineau C, et al. The 1000 Canadian faces of lupus: determinants of disease outcome in a large multiethnic cohort. *J Rheumatol*. 2009;36(6):1200-8.
117. Ball EM, Gibson DS, Bell AL, Rooney MR. Plasma IL-6 levels correlate with clinical and ultrasound measures of arthritis in patients with systemic lupus erythematosus. *Lupus*. 2014;23(1):46-56.

118. Oglesby A, Korves C, Laliberté F, Dennis G, Rao S, Suthoff ED, et al. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes. *Appl Health Econ Health Policy*. 2014;12(2):179-90.
119. Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. *Rheumatology*. 2020;59(Suppl 5):v69-v81.
120. Fanouriakis A, Pamfil C, Rednic S, Sidiropoulos P, Bertsias G, Boumpas DT. Is it primary neuropsychiatric systemic lupus erythematosus? Performance of existing attribution models using physician judgment as the gold standard. *Clin Exp Rheumatol*. 2016;34(5):910-7.
121. Hanly JG, Kozora E, Beyea SD, Birnbaum J. Nervous system disease in systemic lupus erythematosus: current status and future directions. *Arthritis Rheumatol*. 2019;71(1):33-42.
122. Matus S, Burgos PV, Bravo-Zehnder M, Kraft R, Porras OH, Farías P, et al. Antiribosomal-P autoantibodies from psychiatric lupus target a novel neuronal surface protein causing calcium influx and apoptosis. *J Exp Med*. 2007;204(13):3221-34.
123. Govoni M, Bombardieri S, Bortoluzzi A, Caniatti L, Casu C, Conti F, et al. Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. *Rheumatology*. 2012;51(1):157-68.
124. Kang JH, Park DJ, Lee KE, Lee JS, Choi YD, Lee SS, et al. Comparison of clinical, serological, and prognostic differences among juvenile, adult, and late onset lupus nephritis in Korean patients. *Clin Rheumatol*. 2017;36(5):1289-95.
125. Lee YH, Choi SJ, Ji JD, Song GG. Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. *Lupus*. 2016;25(7):727-34.
126. Ruiz-Irastorza G, Ugarte A, Saint-Pastou Terrier C, Lazaro E, Ixart A, Couzi L, et al. Twelve-year retrospective review of bullous systemic lupus

erythematosus in cutaneous and systemic lupus erythematosus patients. *Lupus*. 2012;21(10):1013-20.

127. Singh JA, Cleveland JD. Hospitalized infections in lupus: a nationwide study of types of infections, time trends, health care utilization, and in-hospital mortality. *Arthritis Rheumatol*. 2021;73(4):617-30.
128. Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. *Ann Rheum Dis*. 2020;79(1):39-52.
129. Schmajuk G, Yazdany J, Trupin L, Yelin E. Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus. *Arthritis Care Res*. 2010;62(3):386-92.
130. Zheng Y, Sun Y, Xu D, Chen J, Guo Q, Li J, et al. Autoantibodies linked to organ damage in systemic sclerosis overlap syndrome. *Front Immunol*. 2024;15:1426665. doi:10.3389/fimmu.2024.1426665.

